MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
|Podcasts|January 22, 2019
As Cancer Incidence Changes, So Do Screening Recommendations
Five years ago, the American Cancer Society (ACS) recommended that patients at average risk of colorectal cancer start getting screened at age 50. However, in recent years, cancer incidence has changed, with a growing incidence seen in patients under age 50. Reflecting this change, ACS changed the recommended sceening age to 45 in May 2018.
Advertisement
Five years ago, the American Cancer Society (ACS) recommended that patients at average risk of colorectal cancer start getting screened at age 50. However, in recent years, cancer incidence has changed, with a growing incidence seen in patients under age 50. Reflecting this change, ACS changed the recommended sceening age to 45 in May 2018.
The change stemmed from researchers from the University of Colorado Cancer Center, who published a study taking into account the new numbers of young colorectal cancer patients and concluded that the screening age should be adjusted. During this podcast, we speak with Andrea (Andi) Dwyer, director of the Colorado Cancer Screening Program at the CU Cancer Center and program director at the Colorado School of Public Health.
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
Read more about cancer screening:
Advertisement
Related to this article
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
5